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Multi-drug resistant (MDR) Klebsiella pneumoniae represent a global threat to healthcare due to 25 
lack of effective treatments and high mortality rates. The aim of this research was to explore the 26 
potential of administering zidovudine (AZT) in combination with an existing antibiotic to treat 27 
resistant K. pneumoniae infections. Two MDR K. pneumoniae strains were employed, producing 28 
either the NDM-1 or KPC-3 carbapenemase. Efficacy of combinations of AZT with meropenem were 29 
compared with monotherapies against infections in Galleria mellonella larvae by measuring larval 30 
mortality and bacterial burden. The effect of the same combinations in vitro was determined via 31 
checkerboard and time-kill assays. In vitro, both K. pneumoniae strains were resistant to 32 
meropenem but were susceptible to AZT. In G. mellonella, treatment with either AZT or meropenem 33 
alone offered minimal therapeutic benefit against infections with either strain. In contrast, 34 
combination therapy of AZT with meropenem presented significantly enhanced efficacy compared 35 
to monotherapies. This was correlated with prevention of bacterial proliferation within the larvae but 36 
not elimination. Checkerboard assays showed that the interaction between AZT and meropenem 37 
was not synergistic but indifferent. In summary, combination therapy of AZT with meropenem 38 
represents a potential treatment for carbapenemase-producing MDR K. pneumoniae and merits 39 












Klebsiella pneumoniae belongs to the family Enterobacteriaceae and is part of the normal intestinal 50 
flora of healthy humans. However, K. pneumoniae is also an important opportunistic pathogen and 51 
is a major cause of community and healthcare associated infections (HAIs) such as bloodstream, 52 
urinary tract infections and pneumonias (Navon-Venezia 2017). Infection is often associated with 53 
invasive medical devices or surgery in patients that are immunocompromised [reviewed in (Peleg 54 
and Hooper 2010)]. Compounding the problem, K. pneumoniae is adept at acquiring genes 55 
encoding a range of antibiotic resistance mechanisms via either mutations or mobile genetic 56 
elements [Navon-Venezia 2017]. Acquisition of resistance to third generation cephalosporins via 57 
extended-spectrum beta-lactamases (ESBLs) led to increased use of the antibiotics of ‘last-resort’ – 58 
the carbapenem class of broad-spectrum beta-lactams – resulting in the inevitable selection of 59 
resistance to these also. With increasing incidence of resistance to carbapenems, the prevalence of 60 
multi-drug, or extremely- drug resistant (MDR and XDR respectively), K. pneumoniae strains that 61 
are resistant to nearly all available antibiotics is rising globally (Sanchez 2013). Consequently, there 62 
are only a limited number of antibiotic treatments available (Morrill 2015) resulting in higher mortality 63 
rates (Munoz-Price 2013; Tamma 2017) and unsurprisingly, MDR or XDR K. pneumoniae are 64 
considered an urgent public health threat and a major challenge to the delivery of safe healthcare 65 
(World Health Organisation 2017).  66 
The dearth of novel antibiotic treatments in the pipeline for Gram-negative bacteria means that the 67 
development of alternative treatments based on innovative use of existing drugs is an option. 68 
Clinically, the administration of antibiotic combinations to patients suffering from MDR or XDR K. 69 
pneumoniae infection is often employed as a solution to improve therapeutic outcomes. However, 70 
agreement on the best combinations to use, and evidence of any real benefit, is contested (Tamma 71 
2012). Examples of combination therapies employed with some success include, dual carbapenem 72 
therapy (Souli 2017), ceftazidime with avibactam (Lagace-Wiens 2014), meropenem with 73 
vaborbactam (Lee and Baker 2018), and the polymyxin colistin combined with other antibiotics 74 
(Gutierrez-Gutierrez 2017). Unfortunately, none of these options are ideal particularly because of 75 
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the nephrotoxicity and rise of resistance associated with colistin (Capone 2013), and the inability of 76 
either avibactam or vaborbactam to inhibit metallo-beta-lactamases such as NDM-1. Thus, there is 77 
an urgent clinical need to identify new treatment approaches for MDR or XDR K. pneumoniae 78 
strains that have acquired carbapenemases. 79 
To improve options available for clinicians, the ‘repurposing’ of already approved drugs, whose 80 
primary use is not as antibacterials, as antibiotics could speed up the introduction of new treatment 81 
options, particularly if these compounds are administered in combinations with existing antibiotics 82 
(Cheng 2019; Ejim 2011). One example of a drug that could be ‘repurposed’ as an antibiotic is the 83 
anti-viral drug zidovudine (AZT). AZT is a nucleoside analogue with known bactericidal activity 84 
against Gram-negative bacteria, including K. pneumoniae (Elwell 1987; Lewin and Aymes 1989; 85 
Peyclit 2018). In addition, the drug was efficacious in a mouse model of systemic Escherichia coli 86 
infection (Keith 1989). Upon entering Gram-negative bacterial cells, AZT is phosphorylated by 87 
thymidine kinases, incorporated into DNA, and arrests replication by acting as a DNA chain 88 
terminator (Doleans-Jordheim 2011). A number of recent studies that screened libraries of approved 89 
drugs identified synergistic combinations against Gram-negative bacteria that included AZT (Hind 90 
2019; Ng 2018; Wambaugh 2017). Synergistic combinations of AZT that inhibited MDR, or XDR, K. 91 
pneumoniae in vitro included combinations with the lipopeptide antibiotics colistin (Hu 2019) or 92 
polymyxin B (Lin 2019) that also showed enhanced efficacy compared to monotherapy in murine 93 
infection models. Despite these studies with the lipopeptide antibiotics, most studies of the effect of 94 
AZT in combination with existing antibiotics have been performed in vitro. 95 
The aim of this research was to explore further the potential of administering AZT in combinations 96 
with existing antibiotics to treat infections with MDR pathogens using the Galleria mellonella larvae 97 
infection model. This system permits screening of antibacterial activity in vivo against real infections, 98 
in the presence of a functioning immune system, without the high costs and ethical issues 99 
associated with mammalian infection models. Thus, combination treatments consisting of AZT with 100 
the carbapenem beta-lactam, meropenem, were screened for enhanced efficacy compared to 101 
5 
 
monotherapies in Galleria mellonella larvae infected with carbapenemase-producing strains of K. 102 
pneumoniae.  103 
Materials and Methods 104 
Bacteria and growth media 105 
K. pneumoniae strains were obtained from the National  Collection of Type Cultures (NCTC; 106 
https://www.phe-culturecollections.org.uk/collections/nctc.aspx): NCTC 9633T, an antibiotic 107 
susceptible Type strain, NCTC 13443, producing the NDM-1 metallo-beta-lactamase, and NCTC 108 
13438, producing the KPC-3 carbapenemase (Woodford 2008). NCTC 9633T was included as a 109 
control to illustrate the resistance of the two carbapenemase strains to meropenem. All strains were 110 
grown to stationary phase in Mueller–Hinton broth (MHB; Merck, Darmstadt, Germany) at 37oC with 111 
shaking (at 200 rpm) overnight to prepare inocula for antibiotic efficacy testing in vitro or in vivo. 112 
Drugs and G. mellonella larvae 113 
Meropenem and zidovudine were purchased from Sigma–Aldrich Ltd (Dorset, UK). Stock solutions 114 
of meropenem or AZT were prepared in sterile deionized water with 10% dimethylsulphoxide. Sub-115 
stocks of each drug for injection into larvae were prepared in deionized water. G. mellonella larvae 116 
were obtained from UK Waxworms Ltd (Sheffield, UK).  117 
Antibiotic susceptibility testing in vitro 118 
Minimum inhibitory concentrations (MICs) of antibiotics against the K. pneumoniae strains were 119 
determined in 96-well microplates as previously described (Hill 2014). Briefly, doubling dilutions of 120 
meropenem or zidovudine were prepared in MHB and subsequently inoculated with 1.0 x 106 121 
cfu/mL of either K. pneumoniae strain. Microplates were incubated at 37oC and the MIC was defined 122 
as the concentration(s) present in the first optically clear well after 24 h. 123 
Testing combinations for synergy in vitro 124 
The effect of combinations of meropenem with AZT against both K. pneumoniae strains was carried 125 
out using 96-well microplate assays prepared via doubling dilution of meropenem in MHB followed 126 
6 
 
by subsequent addition of AZT to form a combination checkerboard. Each well was then inoculated 127 
with 1.0 x 106 cfu/mL of either K. pneumoniae strain and microplates were incubated at 37ºC. After 128 
24 h, each well was scored for visible growth and fractional inhibitory concentration index (FICI) 129 
values were calculated for each combination tested. Synergy was defined as FICI ≤0.5 (Eliopoulos 130 
1996). Each K. pneumoniae strain was tested in duplicate. 131 
The effect of meropenem and AZT combinations against both K. pneumoniae strains was also 132 
measured using a time-kill assay. Briefly, tubes containing concentrations of AZT, meropenem or a 133 
combination of both drugs were prepared in MHB broth. A control tube contained only sterile water 134 
in MHB. Drug concentrations were prepared at MIC50 for each strain. Tubes were then inoculated 135 
with 1.0 x 107 cfu/mL of either K. pneumoniae strain. Viability was determined after 0, 2, 4 and 6 h 136 
incubation at 37°C by serial dilution in MHB and plating on Nutrient Agar (Merck, Darmstadt, 137 
Germany). Each experiment was performed in duplicate and results expressed as mean ± standard 138 
error of the mean (SEM).  139 
G. mellonella infection model 140 
Efficacy of meropenem or AZT alone or in combination versus G. mellonella larvae infected with the 141 
K. pneumoniae strains was carried out exactly as described previously (Hill 2014; Krezdorn 2014; 142 
Adamson 2015). G. mellonella at their final instar larval stage were kept at room temperature in 143 
darkness. Larvae weighing within the range of 250 to 350 mg were selected for each experiment to 144 
ensure consistency in subsequent drug administration and were used within 1 week of receipt.  145 
Groups of 15 larvae were infected with inocula (10 µL) of either K. pneumoniae strain containing 146 
increasing numbers of bacteria to determine an appropriate infectious dose for subsequent drug 147 
efficacy studies. Control experiments using a heat-killed inoculum of each strain was carried out in 148 
which the bacterial suspension was heated at 98ºC for 10 min prior to infection of a group of larvae. 149 
For all studies of drug efficacy, an inoculum of 5.6 x 105 cfu, or 9.1 x 107 cfu, was used for K. 150 
pneumoniae NCTC 13443 (NDM-1) and NCTC 13438 (KPC-3), respectively. A single treatment with 151 
phosphate-buffered saline (PBS), meropenem, AZT or a combination of both drugs was 152 
administered 2 h post-infection. The experiments were repeated in duplicate using larvae from a 153 
7 
 
different batch and the data from these replicate experiments were pooled to give n=30. Survival 154 
data were plotted using the Kaplan–Meier method (Bland and Altman 1998) and comparisons made 155 
between groups using the log-rank test (Bland 2004). In all comparisons with the negative control it 156 
was the uninfected control (rather than the unmanipulated control) that was used. Holm’s correction 157 
was applied to account for multiple comparisons in all tests and p ≤ 0.05 was considered significant 158 
(Holm 1979).  159 
Bacterial burden within larvae from each treatment group was measured exactly as described 160 
previously (Krezdorn 2014; Adamson 2015; Ballard and Coote 2016). Groups of 30 larvae were 161 
infected with either strain of K. pneumoniae using the same inoculum sizes as described above. 162 
Meropenem, AZT or a combination treatment of both drugs were administered at 2 h post-infection. 163 
Larvae were incubated in Petri dishes at 37°C. At 24 h intervals, five larvae were randomly selected 164 
from each treatment group and surface decontaminated and anaesthetised by washing in absolute 165 
ethanol. Each larva was then placed in an Eppendorf tube containing 1 mL of sterile PBS and 166 
homogenised using a sterile pestle. Bacterial burden from individual caterpillars was then 167 
determined by serial dilution of the homogenate in MHB and plating on MacConkey agar 168 




Two carbapenemase-producing strains of K. pneumoniae are resistant to meropenem but 173 
sensitive to the antiviral drug AZT. In comparison to the antibiotic-susceptible Type strain, the two 174 
strains producing the carbapenemases displayed resistance to meropenem as expected (Table 1). 175 
The MICs of meropenem were the same for both carbapenemase-producing strains but K. 176 
pneumoniae NCTC 13438, carrying the KPC-3 carbapenemase, was more resistant to AZT (4 mg/L) 177 
than NCTC 13443 with NDM-1 (1 – 2 mg/L). These results confirmed previous studies with different 178 
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strains of K. pneumoniae that showed sensitivity to AZT (Elwell 1987; Lewin and Aymes 1989; 179 
Peyclit 2018).  180 
G. mellonella larvae display dose-dependent lethality in response to infection by either strain 181 
of MDR K. pneumoniae. The effect of infection with either K. pneumoniae strains on survival of G. 182 
mellonella is shown in Figure 1. In both strains, the heat-killed inoculum had no significant effect on 183 
larval survival (p>0.05). With live inocula, larval survival was affected in a dose-dependent manner 184 
during 96 h incubation (Figure 1). Together, these data indicate that infection with live K. 185 
pneumoniae is required to cause larval death and support previous studies that have utilised G. 186 
mellonella to study infection by different K. pneumoniae strains (Insua 2013; Wand 2013; 187 
McLaughlin 2014; Benthall 2015). 188 
K. pneumoniae NCTC 13443 (NDM-1) displayed greater virulence than NCTC 13438 (KPC-3), 189 
requiring a smaller inoculum of viable bacteria to induce a similar degree of lethality to infected 190 
larvae. Infectious doses for each strain were selected for use in subsequent studies on antibiotic 191 
efficacy (5.6 x 105 cfu for K. pneumoniae NCTC 13443, and 9.1 x 107 cfu for NCTC 13438) that 192 
resulted in the death of approximately 90% of larvae after 96 h incubation at 37ºC.  193 
Efficacy of AZT or meropenem monotherapy in G. mellonella larvae infected with either 194 
carbapenemase-producing strain of K. pneumoniae is poor. The effect of single doses of AZT 195 
or meropenem, 2 h post-infection (p.i) with either K. pneumoniae strain, on survival of G. mellonella 196 
larvae is shown in Figure 2. Both drugs increased larval survival in a dose-dependent manner 197 
regardless of the K. pneumoniae strain. However, neither drug induced high levels of therapeutic 198 
benefit, with the exception of AZT versus larvae infected with K. pneumoniae NCTC 13443 (NDM-1) 199 
treated with the highest doses of 6.25 or 12.5 mg/kg. In contrast, treatment of larvae infected with 200 
the KPC-3-producing strain with the same doses of AZT had no therapeutic benefit after 120 h. As 201 
would be expected with these strains, treatment with meropenem induced only low levels of 202 
therapeutic benefit even at the highest doses tested, particularly against infections with K. 203 
pneumoniae NCTC 13438 (KPC-3). 204 
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In summary, neither AZT or meropenem monotherapy offered high levels of therapeutic benefit 205 
versus infections with either strain of carbapenemase-producing K. pneumoniae, although both 206 
drugs were moderately more effective against the NMD-1-producing strain than the KPC-3 strain. 207 
Combination therapy with AZT plus meropenem shows enhanced efficacy compared to 208 
monotherapy versus G. mellonella infections with carbapenemase-producing MDR strains of 209 
K. pneumoniae. The effect of monotherapy, with AZT or meropenem, compared with combination 210 
therapy on survival of G. mellonella larvae, and burden of infecting bacteria, for both 211 
carbapenemase-producing strains of K. pneumoniae is shown in Figure 3. Pilot experiments were 212 
carried out testing many different doses of AZT or meropenem in combination to identify the most 213 
effective doses to employ against larval infections with either strain of K. pneumoniae (data not 214 
shown). From these initial studies, optimal combination dosing regimens were selected that offered 215 
the best therapeutic benefit and subsequently studied in detail – NCTC 13443 (AZT - 0.78 mk/kg + 216 
meropenem - 6.25 mg/kg) and NCTC 13438 (AZT - 6.25 mg/kg + meropenem - 12.5 mg/kg) (Figure 217 
3). 218 
As shown previously (Figure 2), a single dose 2 h p.i of either AZT or meropenem had minimal 219 
therapeutic benefit on larvae infected with either strain of K. pneumoniae (Figure 3). This was 220 
reflected in large increases over 24 h in the internal burden of either infecting K. pneumoniae strain 221 
within individual larvae. For larvae infected with NCTC 13443 (NDM-1), the increase in bacterial 222 
numbers after treatment with either meropenem or AZT was the same as larvae mock treated with 223 
PBS. With strain NCTC 13438 (KPC-3), larvae treated with either meropenem or PBS alone also 224 
displayed an identical increase in bacterial burden after 24 h. Notably, the increase in bacterial 225 
numbers after treatment with AZT was reduced (approximately 0.5 log10 cfu/mL), indicating some 226 
inhibitory effect of the drug on proliferation of strain NCTC 13438 within the larvae. However, this 227 
smaller increase in bacterial numbers post AZT therapy was not reflected in any significant 228 
reduction in larval death compared to treatment with meropenem or PBS (Figure 3). 229 
In direct contrast to monotherapies, a single dose of a combination of AZT + meropenem resulted in 230 
significantly (p ≤ 0.05) enhanced survival of larvae infected with either MDR strain of K. pneumoniae 231 
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(Figure 3). For example, 120 h p.i with NCTC 13443 (NDM-1), populations treated with PBS, AZT 232 
alone or meropenem alone showed survival of 20, 40 and 47% respectively. In contrast, 67% of 233 
larvae treated with the combination survived. At the same time p.i with NCTC 13438 (KPC-3), 234 
treatment with PBS, AZT alone or meropenem alone showed survival of 10, 13 and 17% 235 
respectively compared to 47% for the combination. Correlating with this enhanced survival, the 236 
burden of bacteria within the infected larvae did not show the large increase after 24 h observed 237 
previously with the monotherapies, and, bacterial numbers remained significantly lower throughout 238 
the duration of the experiment (p ≤ 0.05). Whilst the combination treatment halted the proliferation of 239 
infecting bacteria of either strain, numbers did not fall below the initial infecting inoculum size. Thus, 240 
the therapeutic benefit conferred by AZT+ meropenem combination treatment appears to be due to 241 
a bacteriostatic effect in vivo. 242 
In summary, a combination treatment of AZT + meropenem offers a potential novel therapy for 243 
treatment of MDR, carbapenemase-producing strains of K. pneumoniae. 244 
The inhibitory action of the combination of AZT plus meropenem versus K. pneumoniae is 245 
not significantly synergistic in vitro. To help understand the nature of the inhibitory action of the 246 
combination of AZT with meropenem that conferred enhanced efficacy in vivo, checkerboard and 247 
time-kill experiments were conducted in vitro (Figure 4). A checkerboard assay showing the effect of 248 
different AZT and meropenem combinations on growth of both carbapenemase-producing strains of 249 
K. pneumoniae is shown in Figure 4a. For NCTC 13443 (NDM-1), there was some evidence of 250 
minor synergy (FICI ≤ 0.5) at only two combinations tested. The majority of the other combinations 251 
that inhibited growth did so in an indifferent or additive fashion. For strain NCTC 13438 (KPC-3), 252 
none of the inhibitory combinations tested were synergistic, with all displaying indifference or 253 
additivity. 254 
The effect of exposure to the single drugs (at MIC50) and a combination (also at MIC50 for each 255 
drug) on viability of both strains is shown in Figure 4b. Bacterial viability was measured over a 256 
period of 6 h at 37°C. Control populations of both strains, mock treated with PBS increased in cell 257 
number over the duration of the experiment. Exposure to AZT alone resulted in a loss of viability of 258 
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both strains of approximately 3 log10 cfu/mL after 6 h. In contrast, exposure to meropenem also 259 
resulted in loss of viability, but after 6 h exposure, there was evidence from both strains that the 260 
surviving population of bacteria was recovering and growth resuming. With both strains, the 261 
combination treatment resulted in a steady decline in viability of approximately 4 log10 cfu/mL after 6 262 
h. Despite the greater bactericidal effect of the combination compared to the individual drugs, the 263 
loss of viability induced by the combination was only approximately 1 log10 cfu/mL more than AZT 264 
alone. This supports the checkerboard results by showing that the inhibition of K. pneumoniae 265 
induced by exposure to the combination of AZT with meropenem is not strongly synergistic. Notably, 266 
despite being bactericidal, the combination did not eliminate all bacteria over the duration of the 267 
experiment. This observation is supported by the G. mellonella larval burden assays (Figure 3) 268 
where infecting K. pneumoniae were never eliminated and a reduced number of bacteria were 269 
always detectable.   270 
Discussion 271 
The antibacterial properties of AZT have been well documented but the drug has never been 272 
formally approved to treat bacterial infections (Elwell 1987; Lewin and Aymes 1989; Ng 2018). With 273 
the emergence of untreatable infections by MDR, or XDR, Gram-negative bacteria, there has been 274 
renewed interest in exploiting these properties and ‘repurposing’ the drug. In fact, a recent study 275 
proposed using AZT alone as a salvage therapy for colistin-resistant infections (Peyclit 2018). In this 276 
study, AZT was shown to inhibit two MDR, carbapenemase-producing strains of K. pneumoniae with 277 
MICs between 1.0 and 4.0 mg/L, confirming the known inhibitory effect of AZT on this pathogen 278 
(Elwell 1987; Lewin and Aymes 1989; Peyclit 2018). In addition, G. mellonella larvae infected with 279 
the same strains displayed enhanced survival after monotherapy with AZT.  280 
Despite many studies showing that AZT is antibacterial, one reason why the drug may not be highly 281 
effective as a monotherapy is the induction of resistance after short-term exposure (Lewin 1990). 282 
AZT only inhibits bacteria that possess a thymidine kinase that phosphorylates the AZT such that it 283 
can then be incorporated into DNA and arrest DNA replication (Doleans-Jordheim 2011). In E. coli, 284 
mutations, or the presence of insertion sequences, in the gene encoding thymidine kinase (that 285 
12 
 
could result in impaired function of the enzyme) correlated with AZT resistance (Doleans-Jordheim 286 
2011). Furthermore, E. coli strains resistant to AZT have been isolated from patients undergoing 287 
therapy with the drug and the activity of thymidine kinase in these strains was reduced (Lewin 288 
1990). Thus, because of the issue of resistance to AZT, the most likely application of the drug as an 289 
antibacterial therapy for MDR Enterobacteriaceae is in combination therapies with antibiotics that 290 
could help reduce the onset of resistance. 291 
A number of studies have highlighted effective combinations of AZT with various approved 292 
antibiotics in vitro including: tigecycline against MDR E. coli and K. pneumoniae (Ng 2018); colistin 293 
versus colistin-resistant K. pneumoniae (Falagas 2019) or E. coli (Loose 2018; Peyclit 2018); 294 
trimethoprim and/or sulfamethizole against trimethoprim-resistant E. coli and K. pneumoniae clinical 295 
isolates (Wambaugh 2017); and the aminoglycosides, gentamicin and amikacin against E. coli 296 
(Doleans-Jordheim 2011). Notably, two studies demonstrate enhanced efficacy in vivo of AZT in 297 
combination with colistin (Hu 2019) or polymyxin B (Lin 2019), compared to their constituent 298 
monotherapies, in murine infection models with NDM-producing K. pneumoniae and/or colistin-299 
resistant E. coli. In this study, a combination therapy consisting of AZT with meropenem resulted in 300 
enhanced efficacy against infections by two MDR, carbapenemase-producing strains of K. 301 
pneumoniae in G. mellonella larvae compared to each monotherapy. Supporting these findings, a 302 
recent screen of Food and Drug Administration-approved drugs identified that AZT acted as an 303 
antibiotic-resistance breaker (ARB) when combined with meropenem and potentiated the inhibitory 304 
effect of the antibiotic against MDR K. pneumoniae in vitro (Hind 2019). Clearly, only two NCTC 305 
carbapenemase-producing strains were used in this study and additional studies using a range of 306 
carbapenemase-producing clinical isolates will be required to confirm the enhanced efficacy of this 307 
combination. 308 
Despite the enhanced efficacy of the combination, the larval populations treated with the 309 
combinations still suffered mortality for the duration of the experiments albeit less than those treated 310 
with the monotherapies. This observation could be explained by the effect the different treatments 311 
had on the burden of infecting bacteria within the larvae. For example, monotherapies had no 312 
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detrimental effect on the infecting bacteria of either strain because numbers increased rapidly over 313 
the first 24 h in the same fashion as larvae sham-treated with PBS. However, combination therapy 314 
had the effect of preventing infecting bacteria of either strain from proliferating in the larvae but, 315 
notably, did not reduce bacterial burden. The fact that combination-treated larvae still contained 316 
viable bacteria could account for these populations suffering mortality at a reduced rate compared 317 
to populations treated with either monotherapy. These observations in vivo were supported by the 318 
results from the in vitro time-kill experiments. For example, despite the combination of AZT with 319 
meropenem showing a bactericidal effect, lethality slowed over a 6 h period of exposure and low 320 
numbers of either strain survived. Furthermore, the enhanced efficacy of the combination treatment 321 
in vivo was unlikely to be due to a synergistic interaction between AZT and meropenem because 322 
the in vitro experiments largely showed an indifferent or additive effect. The lack of potent synergy 323 
between AZT and meropenem versus the two K. pneumoniae strains could account for the 324 
observed survival kinetics of infected larvae and the failure of the combination treatment to confer 325 
full survival or eliminate all infecting bacteria at the doses tested. It is likely that the enhanced 326 
efficacy of the combination observed in vivo can be explained by the FICI values observed in vitro. 327 
For example, the best FICI value obtained for the NDM-1 strain was 0.5 and for the KPC-3 strain 328 
0.62. These values represent a weak synergistic effect or, at the very least, an indifferent or additive 329 
effect of the combination versus both strains. An additive effect is supported by the time-kill assay 330 
whereby a 6 h exposure to the combination resulted in only approximately 1 log10 cfu/mL greater 331 
reduction in cell numbers than either of the constituent drugs alone.  332 
For therapy of Human Immunodeficiency Virus (HIV), AZT is administered orally at 300 mg twice a 333 
day indicating that blood plasma concentrations above the MIC for K. pneumoniae could be reached 334 
(Peyclit 2018; Falagas 2019). Furthermore, AZT is well-tolerated, and toxicity generally only 335 
manifests after long-term use of the drug – a scenario that would be unlikely if antibiotic/AZT 336 
combinations were used to treat acute bacterial infections.  337 
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In summary, this work has identified that combination of AZT with meropenem represents a 338 
plausible alternative therapy to treat infections with MDR, carbapenemase-producing strains of K. 339 
pneumoniae and merits further investigation. 340 
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Legends for Figures 455 
Figure 1. Effect of increasing inoculum dose of live K. pneumoniae NCTC 13443 (NDM-1) or NCTC 456 
13438 (KPC-3) on the survival of G. mellonella larvae during incubation at 37°C for 120 h. Numbers 457 
in the legend indicate the inoculum size in bacterial cells per larva. For both strains, the effect of 458 
heat-killed (h.k.) bacterial inocula is also shown. No significant mortality was observed in an 459 
unmanipulated group (data not shown) or in the uninfected group mock ‘infected’ with sterile PBS. 460 
For all infected groups, survival was significantly reduced compared to the mock ‘infected’ group 461 
(p<0.05, log rank test with Holm correction for multiple comparisons); n=30 (pooled from replicate 462 
experiments).  463 
Figure 2. Effect of treatment with zidovudine (AZT) or meropenem (MEM) on survival of G. 464 
mellonella larvae infected with K. pneumoniae strains. Groups of larvae were mock ‘infected’ with 465 
sterile PBS, or 5.6 x 105 cells of the NDM-1 strain, or 9.1 x 107 cells of the KPC-3 strain. 2 h post-466 
infection (p.i), a single dose of either MEM or AZT was administered (dose in mg/kg is the number 467 
shown on the figure). The mock ‘treated’ group represents infected larvae treated with sterile PBS. 468 
Larval survival was measured over a period of 120 h at 37°C. * indicates significantly enhanced 469 
survival compared to the mock ‘treated’ group (p<0.05, log rank test with Holm correction for 470 
multiple comparisons); n=30 (pooled from duplicate experiments). 471 
Figure 3. Effect of treatment with combinations of AZT and MEM on the survival and internal 472 
bacterial burden of G. mellonella larvae infected with K. pneumoniae strains. Larvae were infected 473 
with PBS (mock ‘infected’), K. pneumoniae NCTC 13443 (NDM-1) – 5.6 x 105 cells, or  NCTC 13438 474 
(KPC-3) – 9.1 x 107 cells and treated with either PBS (mock ‘treated’), or a single dose of each drug 475 
individually, or a combination of MEM and AZT at 2 h p.i. (dose in mg/kg is the number shown on 476 
the figure). Larvae were incubated at 37oC for 120 h and survival recorded every 24 h.  477 
The larval burden of K. pneumoniae was determined from five individual larvae per treatment group 478 
every 24 h for 96 h at 37oC. Error bars indicate ±SEM.  479 
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 * combination treatment group with significantly enhanced survival compared with any of the 480 
constituent monotherapies (p < 0.05, log-rank test with Holm’s correction for multiple comparisons). 481 
n=30 (pooled from duplicate experiments).  482 
# significant difference in larval burden between groups treated with the combination of AZT + MEM 483 
compared with each monotherapy (p < 0.05, the Mann–Whitney U-test compared the combination 484 
therapy with each monotherapy). n = 5. 485 
Figure 4. The effect of combination of AZT with MEM on the growth and viability of K. pneumoniae 486 
NCTC 13443 (NDM-1) or NCTC 13438 (KPC-3) in vitro. Fractional inhibitory concentration indices 487 
(FICI) of AZT combined with MEM versus NDM-1 and KPC-3 after 24 h in MHB at 37oC (A). Black 488 
squares indicate FICI values where bacterial growth occurred. Grey squares indicate wells where 489 
the FICI values were ≥ 0.5 (indicating inhibition was not synergistic). White squares show FICI 490 
values of 0.5 or less where bacterial growth was inhibited and thus indicate synergistic inhibition of 491 
growth. The experiment was performed in duplicate and a representative result is shown.  492 
Time-kill curves of the effect of 6 h exposure to PBS or MIC50 of; MEM alone (128 mg/L for both 493 
NDM-1 and KPC-3); AZT alone (0.5 mg/L NDM-1 and 2 mg/L KPC-3) or AZT + MEM (NDM-1 – 128 494 
mg/L MEM + 0.5 mg/L AZT; KPC-3 – 128mg/L MEM + 2 mg/L AZT). Error bars indicate ±SEM from 495 










Table 1 – Minimum inhibitory concentration (MIC) of zidovudine (AZT) and meropenem (MEM) for 504 
the K. pneumoniae Type strain or strains possessing either the NDM-1 or KPC-3 carbapenemases. 505 
 506 
 507 
Bacterial Strains                          MIC (mg/L) 
 AZT MEM 
K. pneumoniae NCTC 9633T - <0.0625 
K. pneumoniae NCTC 13443 (NDM-1) 1.0 – 2.0 128 - 256 


























































Figure 4B 555 
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